In his new role, Dr Finnegan will oversee the Phase III clinical program for Transdel’s lead product, Ketotransdel, a novel topical cream based non-steroidal anti-inflammatory drug for the treatment of acute pain. In addition, Dr Finnegan will manage the development and expansion of Transdel’s clinical pipeline, leveraging the company’s proprietary Transdel technology to develop enhanced generic and novel products in a broad range of indications and therapeutic areas.
Dr Finnegan joins the company from Cecoura Therapeutics, a privately held biotechnology firm, where he served as president and CEO from October 2007 to March 2008.
Juliet Singh, president and CEO of Transdel Pharmaceuticals, said: “We are pleased to welcome Dr Finnegan to our senior management team. Dr Finnegan’s knowledge base and capabilities will be integral to supporting our goal of expanding our pipeline with innovative topically based products.”